Cooperative Agreement 2026112

The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $327,864 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Opsin Biotherapeutics Inc. to develop an optogenetic pain modulator for non-opioid chronic pain management. The project aims to optimize the optical delivery and wireless stimulation device for the Multi-Characteristic Opsin (MCO) that can be delivered to pain-sensing neurons and stimulated to minimize pain perception. The...

This $832,886 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) seeks to evaluate a novel, non-pharmacological pain relief device called the Neurocuple for managing postoperative pain in patients undergoing total knee arthroplasty (TKA) surgery. The funded research involves a randomized, placebo-controlled clinical trial with 120 TKA patients to assess the effectiveness of the Neurocuple device in reducing opioid...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $2,505,537 to The Leland Stanford Junior University to develop a focused ultrasound (FUS) device for noninvasive, peripheral nerve blockade to manage acute pain. The goal is to provide an alternative to opioids and current peripheral nerve block techniques, which have significant limitations in acute pain management. The...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $970,052 to Backstop Neural, Inc. to demonstrate the feasibility of a novel, thin, softening epidural stimulation lead to relieve chronic arm and neck pain. The key products and services to be delivered through this Phase I SBIR project include: 1) Design and fabrication of a 16-channel, 0.2 mm thick human-sized softening...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $319,278 to Photopharmics, Inc. to evaluate the efficacy of a novel heterodyned whole body vibration (HWBV) device for treating opioid use disorder (OUD). The key goals of this 1-year Phase I project are to: 1) improve the technical aspects of the HWBV device, implement telemetry, and evaluate physiological indices of anxiety; 2) assess...

This SBIR Phase II award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $2,776,138 to Neurocarrus Inc. to develop a novel biologic drug called N-001 for the management of acute nociceptive pain. The funding will be used to optimize the production and formulation of N-001, establish manufacturing standards and controls, and conduct pivotal preclinical studies to demonstrate the safety and...

This $318,875 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of a machine learning algorithm to detect opioid withdrawal symptoms and cravings using wearable physiologic sensors. The goal is to enable closed-loop delivery of transcutaneous auricular neurostimulation (TAN) therapy to reduce withdrawal symptoms and cravings, thereby increasing treatment retention for individuals with...

This $1,559,917 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research to assess the analgesic efficacy and effects of a topical neurokinin-1 receptor (NK1R) antagonist in managing chronic ocular pain. The key objectives are to determine whether topical NK1R antagonist treatment can effectively reduce chronic ocular pain without causing addiction or ocular side effects, and to...

The National Institute of Neurological Disorders and Stroke awarded a $998,787 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to Brixton Biosciences Inc. to develop a novel injectable cryoneurolysis treatment for reducing post-surgical pain following total knee arthroplasty. The goal is to create an opioid-sparing, nerve-selective cryoneurolysis method that can be injected around sensory nerves to reversibly disrupt pain signals for up to 8 weeks. The project aims to...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $800,000 to Tenvos Inc., a minority-owned and woman-owned small business, to develop a software-based medical device for detecting opioid use through voice analysis. The key objectives of this 1-year project are to: 1) collect clinical data and patient voice samples to study the correlation between voice patterns and opioid use; 2) validate...